DOTA-NHS-ester
DOTA-NHS-ester
Résumé du produit
Aperçu rapide
- Famille de produits
- ADC Linkers & Conjugation Reagents
- Nom chimique
- DOTA-NHS-ester
- FM
- C20H31N5O10
- PM
- 501.5
DOTA-NHS-ester is a DOTA-family NHS ester identified by CAS 170908-81-3.
This record matches molecular formula C20H31N5O10, molecular weight about 501.5, and PubChem CID 11488945.
Use the DOTA-NHS-ester name with CAS 170908-81-3 when comparing catalog and external database records.
Identité et spécifications
| Catalog No. | CH53020 |
| CAS No. | 170908-81-3 |
| Chemical Name | DOTA-NHS-ester |
| Molecular Formula | C20H31N5O10 |
| Molecular Weight | 501.5 |
| PubChem CID | 11488945 |
Contexte d’application
- DOTA NHS ester identity reference: supports matching DOTA-NHS-ester with CAS 170908-81-3 and PubChem CID 11488945.
- DOTA-conjugate research: supporting literature places DOTA NHS ester chemistry in DOTA-conjugate research records.
- Identifier alignment: useful when formula, molecular weight, CAS number, and PubChem identity need to be checked together.
Informations complémentaires sur le matériau
Utilisations
Useful for aligning DOTA-NHS-ester with CAS 170908-81-3, formula C20H31N5O10, molecular weight about 501.5, and PubChem CID 11488945.
Caractéristiques
- DOTA-family compound with an NHS ester identity.
- CAS and product-name lookups both resolve to PubChem CID 11488945.
- This page represents the product as a DOTA-chelator identity rather than generic category wording.
Ressources techniques associées
Chimie des espaceurs et charges utiles pour ADC
Espaceurs clivables ou stables, segments hydrophiles, fonctions réactives sélectives et intermédiaires espaceur-charge utile.
espaceurs ADC clivables vs non clivables
Comparer espèce libérée, déclencheur, stabilité en circulation, traitement cellulaire, charge, conjugaison et preuves analytiques.
Sources publiques
- Tetraxetan N-hydroxysuccinimide | PubChem CID 11488945
- Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
Bioconjugate Chemistry, 2016
Product-family technical context
- Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs
Journal of Pharmaceutical Sciences, 2020
Product-family technical context
- Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing
Cancer Research, 2006
Product-family technical context
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Molecular Cancer Therapeutics, 2012
Product-family technical context
Questions fréquentes
Which research appears in the references?
Supporting references include DOTA-conjugate research; this page keeps the product identity tied to CAS 170908-81-3 and PubChem CID 11488945.
Produits similaires
Besoin d’aide pour sélectionner un matériau ?
CHEMOS peut examiner l’adéquation produit, la structure cible, les questions de voie, les attentes analytiques et les besoins d’approvisionnement du projet.